---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-009641"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T02:51:49.498976+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Journey Medical expects $20.3M cash; reaffirms FY2024 revenue guidance $55-60M

## Summary
- Cash and cash equivalents expected to be $20.3 million as of December 31, 2024.
- Reaffirms FY2024 guidance: net product revenue $55-60M, SG&A $39-42M, R&D $8-10M.
- Hosts Feb 5, 2025 conference call to update commercial launch plan for Emrosi (minocycline HCl ER 40 mg).
- Investor presentation (Exhibit 99.1) attached but specific slide content not disclosed in filing.

## SEC filing metadata
- accession: 0001104659-25-009641
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465925009641/0001104659-25-009641-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465925009641/tm255603d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-009641
- JSON: https://secwatch.observer/filing/0001104659-25-009641.json
- Plain text: https://secwatch.observer/filing/0001104659-25-009641.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.